Evaluation of clinical prognostic factors in Polish interferon beta-1b treated multiple sclerosis patients.
CONCLUSIONS: Rio, modified Rio, early NEDA on treatment and BREMSO score are relatively specific, but insensitive, predictors of relapse activity in the first years of IFNβ-1b treatment. Higher pre-treatment EDSS and relapse activity is associated with disability progression, but not overall NEDA, in subsequent observation. While none of the markers is sufficiently sensitive or specific to make a certain prognosis, they may aid treatment decisions in patients with continued early disease activity. PMID: 31793659 [PubMed - as supplied by publisher] (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - December 3, 2019 Category: Neurology Authors: Pietrzak A, Kalinowska-Łyszczarz A, Kozubski W, Michalak S Tags: Neurol Neurochir Pol Source Type: research

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis
In 1993, the first disease modifying-therapy (DMT) for multiple sclerosis (MS), interferon beta-1b, was approved, and an untreatable disease that had disabled humans for hundreds of years became treatable. Since then, multiple drugs with varying mechanisms of action have been approved, and neurologists now have a palette of therapies that allows for individualizing therapy and effectively controlling relapsing MS in most patients. Regrettably, this achievement has come at a steep price. Interferon beta-1b entered the market with an annual price of approximately $10  920 ($19 313, inflation adjusted). While this price s...
Source: JAMA Neurology - August 26, 2019 Category: Neurology Source Type: research

Functional Deimmunization of Interferon Beta-1b by Identifying and Silencing Human T Cells Epitopes.
Abstract Interferonbeta-1b (IFNβ-1b) developed as therapeutic protein for the treatment of multiple sclerosis (MS). Studies have been shown that Long-term usage of this protein can lead to the development of anti-drug antibodies (ADAs) and this phenomenon cause total loss or reduced efficacy of IFNβ-1b. The aim of this study was to predict and silence IFNβ-1b T-cells epitopes by in silico methods and genetic engineering. Based on bioinformatics studies we identified optimal sets of conservative point mutations for eliminating T-cells epitopes in IFNβ-1b protein. Four synthetic genes with desira...
Source: Iranian Journal of Allergy, Asthma and Immunology - August 17, 2019 Category: Allergy & Immunology Authors: Moradi Hasan-Abad A, Adabi E, Sadroddiny E, Khorramizadeh MR, Mazlomi MA, Mehravar S, Kardar GA Tags: Iran J Allergy Asthma Immunol Source Type: research

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority
Conclusions: A calendar with CW was non-inferior than FR at the beginning of IFN-b therapy, and may not affect the long-term outcome. Clinicaltrial.gov identifiers: NCT00270816 (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - July 16, 2019 Category: Neurology Source Type: research

Immunological Aspects of Approved MS Therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The disease’s course is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the disease’s course. Over the past two decades, the disease’s treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 10 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponim...
Source: Frontiers in Immunology - July 11, 2019 Category: Allergy & Immunology Source Type: research

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
Conclusion: Patients with isolated thalamic atrophy were at a higher risk for not reaching 2-year NEDA-3 and for EDSS increase than patients with no identified brain atrophy. The groups were clinically indistinguishable. A single measurement of thalamic and whole brain atrophy could help identify patients needing most effective therapies from early on. Introduction The quantification of brain atrophy by MRI has become an increasingly important part of evaluating neurodegeneration in MS (1, 2). Atrophy measures can reflect the damage on the central nervous system (CNS) caused by the pathological processes of the dis...
Source: Frontiers in Neurology - May 3, 2019 Category: Neurology Source Type: research

Multiplexed Gene Expression as a Characterization of Bioactivity for Interferon Beta (IFN- β) Biosimilar Candidates: Impact of Innate Immune Response Modulating Impurities (IIRMIs)
AbstractRecombinant human interferon- β (rhIFN-β) therapy is the first-line treatment in relapsing-remitting forms of multiple sclerosis (MS). The mechanism of action underlying its therapeutic activity is only partially understood as IFN-βs induce the expression of over 1000 genes modifying multiple immune pathways. Currently, asses sment of potency for IFN-β products is based on their antiviral effect, which is not linked to its therapeutic effect. Here, we explore the use of a multiplexed gene expression system to more broadly characterize IFN-β bioactivity. We find that MM6 cells stimulated wit...
Source: The AAPS Journal - February 8, 2019 Category: Drugs & Pharmacology Source Type: research

Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis.
Authors: Napier J, Rose L, Adeoye O, Hooker E, Walsh KB Abstract The secondary inflammatory injury following intracerebral hemorrhage (ICH) results in increased morbidity and mortality. White blood cells have been implicated as critical mediators of this inflammatory injury. Currently, no medications have been clinically proven to ameliorate or beneficially modulate inflammation, or to improve outcomes by any mechanism, following ICH. However, other neuroinflammatory conditions, such as multiple sclerosis, have approved pharmacologic therapies that modulate the inflammatory response and minimize the damage caused b...
Source: Immunopharmacology and Immunotoxicology - February 2, 2019 Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
ConclusionTeriflunomide is a cost-effective therapy over a lifetime time horizon compared to interferon beta-1b in the treatment of RMS patients in China. Results should be interpreted with caution as head-to-head comparisons are not available. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - January 25, 2019 Category: Drugs & Pharmacology Source Type: research

Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study
AbstractMultiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) with a diverse disease course involving inflammation and degeneration of neurons and axons. Multiple sclerosis results from a complex interaction of genetic and environmental factors and clinically several disease subtypes with marked variation in symptoms can be discerned. Disease-modifying therapies (DMTs) impact disease activity and outcome. Long-term follow-up studies of DMTs in MS have generally shown that the short-term effects in clinical trials are maintained for up to 21 years, e.g. in the case of interferon beta-1b. Howev...
Source: Journal of Neurology - January 4, 2019 Category: Neurology Source Type: research

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
CONCLUSION: The analysis shows that alemtuzumab is a cost-saving alternative to treat RRMS in pretreated and therapy naïve patients. From the patient perspective alemtuzumab improves quality of life. PMID: 30522373 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 15, 2018 Category: Health Management Tags: J Med Econ Source Type: research

In silico analysis of different signal peptides to discover a panel of appropriate signal peptides for secretory production of Interferon-beta 1b in Escherichia coli.
The objective of this study was to identify a panel of signal peptides (among the 90 biologically active SPs) required for the secretory production of interferon-beta 1b (IFN-beta 1b) recombinant protein into the periplasmic space of E. coli host. In the initial step, after predicting the accurate locations of the cleavage sites of signal peptides and their discrimination scores using SignalP 4.1 server, 31 SPs were eliminated from further analysis because their discrimination scores were less than 0.5 or their cleavage sites were inappropriately located. Therefore, only 59 SPs could be theoretically applied to secrete IFN...
Source: Acta Biochim Pol - October 31, 2018 Category: Biochemistry Authors: Ghovvati S, Pezeshkian Z, Mirhoseini SZ Tags: Acta Biochim Pol Source Type: research

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry
AbstractNeuroanatomical pattern classification using support vector machines (SVMs) has shown promising results in classifying Multiple Sclerosis (MS) patients based on individual structural magnetic resonance images (MRI). To determine whether pattern classification using SVMs facilitates predicting conversion to clinically definite multiple sclerosis (CDMS) from clinically isolated syndrome (CIS). We used baseline MRI data from 364 patients with CIS, randomised to interferon beta-1b or placebo. Non-linear SVMs and 10-fold cross-validation were applied to predict converters/non-converters (175/189) at two years follow-up ...
Source: Brain Imaging and Behavior - August 28, 2018 Category: Neurology Source Type: research

Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study
Sleep disorders and fatigue are common in multiple sclerosis (MS). The underlying causes are not fully understood, and prospective studies are lacking. Therefore, we conducted a prospective, observational coho... (Source: BMC Neurology)
Source: BMC Neurology - August 24, 2018 Category: Neurology Authors: Sylvia Kotterba, Thomas Neusser, Christiane Norenberg, Patrick Bussfeld, Thomas Glaser, Martin D örner and Markus Schürks Tags: Research article Source Type: research

A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.
Conclusions: Our results showed that alemtuzumab can be considered as more effective and less costly than the other treatment alternatives. There is a substantial potential cost saving if more patients start on the more effective and less costly treatment alternatives. PMID: 29317954 [PubMed] (Source: Clin Med Res)
Source: Clin Med Res - January 12, 2018 Category: Research Authors: Hamidi V, Couto E, Ringerike T, Klemp M Tags: J Clin Med Res Source Type: research

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing –remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
This study attempted evaluating the effects of fingolimod and interferon beta-1b (IFN β-1b) on CI progression, magnetic resonance imaging (MRI) and clinical outcomes in relapsing–remitting MS (RRMS) patients over 18 months. The GOLDEN study was a pilot study including RRMS patients with CI randomised (2:1) to fingolimod (0.5 mg daily)/IFN β-1b (250 µg every other day). CI was assessed via Rao’s Brief Repeatable Battery and Delis–Kaplan Executive Function System test. MRI parameters, Expanded Disability Status Scale scores and relapses wer e measured. Overall, 157 patients we...
Source: Journal of Neurology - October 23, 2017 Category: Neurology Source Type: research

Real World Characteristics and Perceived Efficacy of Peginterferon Beta-1A Compared with Other Platform Injectable Therapies Among MS Patients: Evidence in Five European Countries
Describe the demographic and disease characteristics of peginterferon beta-1a patients in a real world data set, and compare perceived effectiveness and quality of life of multiple sclerosis (MS) patients treated with peginterferon beta-1a versus other platform injectable therapies (IM interferon beta-1a, SC interferon beta-1a, interferon beta-1b, glatiramer acetate) in five European countries. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: L Ruiz, J Zhou, C Wakeford, W Huang, Q Hou Source Type: research

Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain
This study assesses cost-effectiveness of subcutaneous (SC) peginterferon beta-1a 125 mcg SC every two weeks vs. other first-line injectable disease-modifying therapies (DMTs) such as glatiramer acetate 40mg SC daily, interferon beta-1a 30mcg intramuscular (IM) once a week, interferon beta-1a 44mcg SC three times a week, and interferon beta-1b 250mcg SC every other day, in the treatment of relapsing remitting multiple sclerosis (RRMS) from the payer perspective in Spain, over a 30-year time horizon (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: L Ruiz, H Toro-Diaz, C Cele, L Hernandez, A Harrington Source Type: research

Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran
In the era of representing new medicines for the treatment of Multiple sclerosis, a highly debilitating immune mediated disorder, evaluating the incremental cost-effectiveness of medicines are necessary for allocating health care resources in an efficient manner. Therefore, this study was aimed to to assess the cost-effectiveness of Alemtuzumab (ALM) in comparison with Natalizumab (NTZ), intramuscular interferon beta-1a (IM-IFN), subcutaneous interferon beta-1b (SC-IFN), and fingolimod (FNG) for the treatment of relapsing-remitting multiple sclerosis (RRMS) from Iranian healthcare perspective. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: S Taheri, N Yousefi, MA Sahraian, G Mehralian Source Type: research

Multiple Sclerosis and Subsequent Human Immunodeficiency Virus Infection: A Case with the Rare Comorbidity, Focus on Novel Treatment Issues and Review of the Literature
Conclusion: This fact, in combination with the unique pharmaceutical composition of the drug, which contains a component similar to a newly-approved agent for MS, dimethyl fumarate, prompted us to review the literature regarding this rare comorbidity and to suggest that the role of the antiretroviral therapy should be further explored in MS. (Source: In Vivo)
Source: In Vivo - September 7, 2017 Category: Research Authors: SKARLIS, C., GONTIKA, M., KATSAVOS, S., VELONAKIS, G., TOULAS, P., ANAGNOSTOULI, M. Tags: Clinical Studies Source Type: research

Aseptic steatonecrosis in a patient with multiple sclerosis with interferon-beta 1b treatment.
Authors: Ramos L, Busca C, Robles A PMID: 28864085 [PubMed - as supplied by publisher] (Source: Medicina Clinica)
Source: Medicina Clinica - September 3, 2017 Category: General Medicine Tags: Med Clin (Barc) Source Type: research

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis
Conclusions: The presence of enhancing lesions affecting the cortex and adjacent white matter, although transient and not frequent, suggests that at least some cortical lesions are related to blood–brain barrier disruption. Our data support the concept that there may be an acute inflammatory phase in the development of leukocortical MS lesions. Clinicaltrials.gov identifier: NCT00176592. (Source: Neurology)
Source: Neurology - August 14, 2017 Category: Neurology Authors: Maranzano, J., Rudko, D. A., Nakamura, K., Cook, S., Cadavid, D., Wolansky, L., Arnold, D. L., Narayanan, S. Tags: MRI, Multiple sclerosis ARTICLE Source Type: research

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
CONCLUSIONS: Very low-quality evidence suggests a small and uncertain benefit with early treatment compared with placebo in reducing disability-worsening and relapses. The advantage of early treatment compared with delayed on disability-worsening was heterogeneous depending on the actual drug used and based on very low-quality evidence. Low-quality evidence suggests that the chances of relapse are less with early treatment compared with delayed. Early treatment reduced the hazard of conversion to CDMS compared either with placebo, no treatment or delayed treatment, both in short- and long-term follow-up. Low-quality eviden...
Source: Cochrane Database of Systematic Reviews - April 25, 2017 Category: Journals (General) Authors: Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G Tags: Cochrane Database Syst Rev Source Type: research

Ocrelizumab (Ocrevus) for MS
Date: June 19, 2017 Issue #:  1523Summary:  The FDA has approved ocrelizumab (Ocrevus– Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS. (Source: The Medical Letter)
Source: The Medical Letter - April 19, 2017 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Betaseron Cladribine Copaxone daclizumab dimethyl fumarate Extavia Fingolimod Gilenya Glatiramer Glatopa Interferon beta IVIG Lemtrada Methotrexate mitoxantrone Multiple sclerosis Natalizuma Source Type: research

Final results from the BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS (P1.346)
Conclusions:Final results from BETAPAEDIC suggest that IFNB-1b is an effective treatment with a favorable tolerability profile for pediatric patients with RRMS.Study Supported by: Bayer HealthcareDisclosure: Dr. Gaertner has received personal compensation from Bayer Vital, Biogen, Merck Serono, Teva, and Novartis as a consultant and for honoraria. Dr. Gaertner has received research support from Novartis and Biogen. Dr. Brueck has received personal compensation for activities with Bayer Vital, Biogen, Merck Serono, Teva Pharma, Genzyme, Sanofi Aventis, and Novartis as a lecturer or member of scientific advisory boards. Dr. ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Gartner, J., Bruck, W., Weddige, A., Hummel, H., Norenberg, C., Bugge, J.-P. Tags: Pediatric Multiple Sclerosis Source Type: research

MSDx Complex-1: A potential marker of drug response? (P1.406)
Objective:Develop a plasma marker to identify drug responders in MSBackground:We have discovered an extremely large (400–1000KD) protein complex in plasma that may be a pharmacodynamic marker in MS.Design/Methods:We designed a synthetic peptide that binds to this complex and created a competitive peptide binding assay to measure the levels of this protein complex in plasma. Plasma was obtained from the Barrow Neurology Institute (Phoenix, AZ and, the Accelerated Cure Project (ACP, Waltham, MA).Results:Twenty-five apparently healthy controls (aHC) and 177 subjects with MS were studied. aHC mean level was 2.18 ng/mL. R...
Source: Neurology - April 17, 2017 Category: Neurology Authors: White, V., Nayak, R. Tags: Biomarkers and Experimental Studies for Multiple Sclerosis I Source Type: research

Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis (P3.401)
Objective:Compare real-world costs of initiation of disease-modifying therapy (DMT) for patients with multiple sclerosis (MS).Background:Truven’s Commercial Claims and Encounters database (2010–2014) was used to evaluate costs.Design/Methods:The study considered a 6-month pre-period and 3-month post-period, including patients aged ≥18 years who initiated on a DMT. Patients were required to have a prescription for the index DMT in the last month of the post-period and to have continuous insurance coverage over the study period. Total monitoring costs (in 2014 US dollars) included costs associated with laborat...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Lage, M. L., Wu, Y. Tags: Economic Implications of Multiple Sclerosis Source Type: research

Interferon beta-1b efficacy in real-life clinical setting: a long-term follow-up study (p6.354)
Conclusions:Our post-marketing experience provides further evidence of sustained IFN beta-1b efficacy in modifying the natural course of MS.Disclosure: Dr. Totaro has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva as a speaker. Dr. Di Carmine has nothing to disclose. Dr. Sciamanna has nothing to disclose. Dr. Marini has nothing to disclose. Dr. Carolei has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Totaro, R., Di Carmine, C., Sciamanna, S., Marini, C., Carolei, A. Tags: Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes I Source Type: research

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms
Conclusion A better definition of what constitutes a relapse in MS is urgently needed. From a treatment perspective, the management of relapses, particularly in the emergency department (ED), is highly variable. In general, it is possible that patients are treated with steroids based on symptomatology and an ED physician’s evaluation. It is often difficult in the ED to ascertain baseline status or a deviation from it, and an MRI may or may not be performed in the ED owing to cost and availability. However, if objective MRI data are not the singular surrogate biomarker to validate BBB breach, false-positive cases are ...
Source: Innovations in Clinical Neuroscience - April 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Commentary Current Issue Devices Evaluations Multiple Sclerosis Neurology Technology acute relapse big data blood brain barrier imaging magnetic resonance imaging MRI MS Source Type: research

Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report
Conclusion—Ketamine may be an alternative treatment for resistant depression and may have a special use in patients with multiple sclerosis. Introduction Depression is a frequent finding in patients with multiple sclerosis (MS), with the lifetime prevalence rates for major depressive disorder (MDD) ranging from 36 to 54 percent, more than twice of that in the general population.[1] Even with advances in pharmacological options for treating depression, an estimated 33 to 66 percent of patients with MDD in the general population do not respond to the first antidepressant, and a reported 15 to 33 percent of patients do ...
Source: Innovations in Clinical Neuroscience - February 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Depression Multiple Sclerosis Neurology Psychiatry Psychopharmacology Electroconvulsive therapy Ketamine major depressive disorder treatment-resistant depression Source Type: research

Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.
Authors: Einarson TR, Bereza BG, Machado M Abstract BACKGROUND: Differences between interferons have been evaluated for over 20 years. While RCT data are mainly used for assessments and strong data for causal inferences, they do not necessarily reflect everyday practice. Real-world data may provide additional information. PURPOSE: To assess the results, quality, and representativeness of observational studies directly comparing IFNs in RRMS. METHODS: Medline and Embase were searched for observational studies comparing IFN-beta-1a 30 mcg IM (Avonex), IFN-beta-1a 44 mcg SC (Rebif) and/or IFN-bet...
Source: Current Medical Research and Opinion - December 29, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: multicentric cross-sectional survey in the western balkan countries
Conclusion TS with IFN beta-1b was high in our MS patients. Additionally, these results have demonstrated that patient support program have significant impact on TS with IFN beta-1b in the Balkan cohort of RRMS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 8, 2016 Category: Neurology Source Type: research

Comparative evaluation of patients ’ and physicians’ satisfaction with interferon beta-1b therapy
Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients ’ perception of treatment efficacy. T... (Source: BMC Neurology)
Source: BMC Neurology - September 21, 2016 Category: Neurology Authors: Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler and Michael Hecker Source Type: research

Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options
AbstractMultiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system. MS is increasingly recognized in the pediatric population, and it is usually diagnosed around 15  years of age. The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial disease. The disease in children almost always presents in the relapsing-remittent form. The therapy involves treat ment of relapses, and immunomodulatory and symptomatic treatment. The treatment of children with MS has...
Source: Neurology and Therapy - September 17, 2016 Category: Neurology Source Type: research

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Conclusions: Although the delay in treatment was relatively short, several clinical outcomes favored earlier treatment. Along with low rates of disability and disease progression in both groups, this supports the value of treatment at CIS. ClinicalTrials.gov identifier: NCT01795872. Classification of evidence: This study provides Class IV evidence that early compared to delayed treatment prolongs time to CDMS in CIS after 11 years. (Source: Neurology)
Source: Neurology - September 5, 2016 Category: Neurology Authors: Kappos, L., Edan, G., Freedman, M. S., Montalban, X., Hartung, H.-P., Hemmer, B., Fox, E. J., Barkhof, F., Schippling, S., Schulze, A., Pleimes, D., Pohl, C., Sandbrink, R., Suarez, G., Wicklein, E.-M., For the BENEFIT Study Group Tags: Multiple sclerosis ARTICLE Source Type: research

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon {beta}-1b
Objective: To compare magnetization transfer changes in new brain MRI lesions identified during monthly imaging in patients with multiple sclerosis (MS) randomized to treatment with 250 μg subcutaneous interferon-β-1b (IFN-β-1b) every other day or daily 20 mg glatiramer acetate (GA) in a post hoc study using data from the Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME) trial. Methods: T1-weighted images acquired with and without fat saturation pulses in the BECOME study were evaluated and found to exhibit magnetization transfer ratio (MTR) effects, a...
Source: Neurology - August 29, 2016 Category: Neurology Authors: Brown, R. A., Narayanan, S., Stikov, N., Cook, S., Cadavid, D., Wolansky, L., Arnold, D. L. Tags: MRI, MTI, Multiple sclerosis ARTICLE Source Type: research

Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon- β treatment in patients with chronic viral cardiomyopathy
ConclusionsImmunomodulatory IFN- β-1b treatment is a well-tolerated and safe treatment option, leading to effective virus clearance or reduction of the virus load in patients with chronic viral cardiomyopathy. Favourable clinical effects assess quality of life, NYHA functional class, and patient global assessment.ClinicalTrials.gov identifier: NCT001185250 (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - August 19, 2016 Category: Cardiology Source Type: research

Care of persons with MS in clinical practice: Management by majority
The mid-1990s saw the advent of a new therapeutic era for multiple sclerosis (MS) with the approval of injectable disease-modifying therapies for relapsing-remitting MS. Despite some differences in routes of injection, frequency of administration, and adverse effects, the 4 initial therapies (interferon-β-1b, interferon-β-1a IM, interferon-β-1a subcutaneous, and glatiramer acetate) were remarkably similar in efficacy and generally safe. In the last 10 years, the landscape has changed dramatically. In addition to the initial 4 injectable therapies and new formulations of 2 of those therapies, 3 oral therapies...
Source: Neurology Clinical Practice - August 15, 2016 Category: Neurology Authors: Marrie, R. A., Racke, M. K. Tags: Multiple sclerosis Editorial Source Type: research

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon {beta}1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
Conclusions: Our results suggest that the combination of atorvastatin and interferon β1b is not justified in early relapsing–remitting multiple sclerosis and adds to the body of evidence indicating an absence of significant radiological and clinical benefit of statins in relapsing–remitting multiple sclerosis. (Source: Multiple Sclerosis)
Source: Multiple Sclerosis - July 26, 2016 Category: Neurology Authors: Lanzillo, R., Quarantelli, M., Pozzilli, C., Trojano, M., Amato, M. P., Marrosu, M. G., Francia, A., Florio, C., Orefice, G., Tedeschi, G., Bellantonio, P., Annunziata, P., Grimaldi, L. M., Comerci, M., Brunetti, A., Bonavita, V., Alfano, B., Marini, S., Tags: Original Research Papers Source Type: research

Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey
Conclusion: In a connected model of patient satisfaction, effectiveness, side effects, convenience and adherence, patients’ individual needs and concerns have to be addressed. Most differences were found with respect to side effects and convenience of treatment. Therefore, an improvement in these two domains seems to be the most promising proximate approach to elevate adherence levels. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - June 21, 2016 Category: Neurology Authors: Haase, R., Kullmann, J. S., Ziemssen, T. Tags: Original Research Source Type: research

Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors
Conclusion BETACONNECT attributes and features were highly rated by patients, compared with both an ideal autoinjector and their current mechanical autoinjectors. These findings suggest that the use of BETACONNECT may increase patient satisfaction and potentially increase overall medication adherence. Funding Bayer HealthCare Pharmaceuticals. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 8, 2016 Category: Neurology Source Type: research

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Conclusion Compared with placebo, clear reductions in ARR with disease-modifying therapies were accompanied by more uncertain changes in disability progression. The magnitude of the reduction and the uncertainty associated with treatment effects varied between DMTs. While natalizumab and alemtuzumab demonstrated consistently high ranking across outcomes, with older interferon-beta and glatiramer acetate products ranking lowest, variation in disability progression definitions lead to variation in the relative ranking of treatments. Rigorously conducted comparative studies are required to fully evaluate the comparative treat...
Source: Multiple Sclerosis and Related Disorders - June 8, 2016 Category: Neurology Source Type: research

[Correspondence] Why use sex hormones in relapsing-remitting multiple sclerosis?
I read with interest Rhonda Voskuhl and colleagues' report1 of a phase 2 trial of the combination of estriol and glatiramer acetate for women with relapsing-remitting multiple sclerosis, and Annette Langer-Gould's Commentary2 on the Article. However, the authors did not seem to be aware of the immunomodulatory effect during pregnancy of interferon tau, which is produced by trophoblast cells in the human placenta.3 The structure and effects of this interferon are similar to those of interferon beta-1a (Rebif, Avonex) and interferon beta-1b (Betaseron, Biogen, Cambridge, MA, USA). (Source: Lancet Neurology)
Source: Lancet Neurology - June 7, 2016 Category: Neurology Authors: Richard Lechtenberg Tags: Correspondence Source Type: research

Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain
Conclusion Early treatment with IFNβ-1b after a CIS vs. delayed treatment is efficient from a social perspective, but it may not be efficient from the perspective of the NHS which does not take non health-related costs into account. (Source: Neurologia)
Source: Neurologia - May 17, 2016 Category: Neurology Source Type: research

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
The objective of the study was to compare depression incidence in relapsing–remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND trial. 891/897 (99 %) of English, French, Spanish and Italian speakers among 2244 patients randomized (2:2:1) to receive either IFNB-1b 500 µg, 250 µg, or GA 20 mg QD for 2–3.5 years submitted Beck Depression Inventory Second Edition (BDI-II) scores at screening and serially thereafter, in which scores ≥14 indicated depression. Baseline BDI-II scores ≥14 were reported in 232/891 patients (26.3&...
Source: Journal of Neurology - May 13, 2016 Category: Neurology Source Type: research

Health Economic Evaluation Of Interferon Beta 1b Versus 1a For Patients Diagnosed With Relapsing Remitting Multiple Sclerosis
The objective of this study is to conduct a health economic evaluation and compare the health care costs associated with patients diagnosed with relapsing remitting multiple sclerosis and taking Interferon beta 1b (Extavia) or Interferon beta 1a (Rebif) subcutaneously. (Source: Value in Health)
Source: Value in Health - May 1, 2016 Category: Global & Universal Authors: M Greene, N Greene Source Type: research

Comparison Of Characteristics Of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis And Taking Subcutaneously Administered Disease Modifying Therapies: Interferon Beta 1b Versus 1a
The objective of this study is to assess and compare the characteristics of relapsing remitting multiple sclerosis (RRMS) patients taking Interferon beta 1b (Extavia) or Interferon beta 1a (Rebif) subcutaneously. (Source: Value in Health)
Source: Value in Health - May 1, 2016 Category: Global & Universal Authors: M Greene, N Greene Source Type: research

Cost-Utility Analysis of Intramuscular Interferon Beta-1b Versus Subcutaneous Interferon Beta-1b and Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in Colombia
To determine cost-utility of interferons intramuscular beta-1-a (IFNβ-1a-IM), subcutaneous beta-1-a (IFNβ-1a-SC), subcutaneous beta-1-b (IFNβ-1b-SC) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in Colombia. (Source: Value in Health)
Source: Value in Health - May 1, 2016 Category: Global & Universal Authors: J Ordoñez, A Delgado Source Type: research

Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy
Conclusions Immunomodulatory IFN-β-1b treatment is a well-tolerated and safe treatment option, leading to effective virus clearance or reduction of the virus load in patients with chronic viral cardiomyopathy. Favourable clinical effects assess quality of life, NYHA functional class, and patient global assessment. ClinicalTrials.gov identifier: NCT001185250 (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - April 25, 2016 Category: Cardiology Source Type: research

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary
Conclusion Persistence in this study was in the published range of observational MS studies. Furthermore, in male patients continuation of therapy might be positively influenced by use of a PDA, and both female and male patients might benefit from an integrated reminder function. In conclusion, electronic diaries reminding patients of upcoming injections can promote an improved adherence to MS therapy. Trial registration ClinicalTrials.gov identifier: NCT00902135. Funding Bayer Vital GmbH. (Source: Advances in Therapy)
Source: Advances in Therapy - April 18, 2016 Category: Drugs & Pharmacology Source Type: research